Page 1

valbiotis LABORATOIRE Press release • • • First - half 2026 results Sales organization , product offering , international : three catalysts fully activated to accelerate sales France : a sales organization now fully operational ( 3 regional directors , 19 medical promotion officers ) , supported by 25 partner pharmacy groups bringing together nearly 4,800 pharmacies ; 599 client pharmacies ( + 26 % in six months ) A complete Valbiotis PRO® range following the launch of Valbiotis PRO® Foie : four solutions with clinically demonstrated efficacy and first - rate scientific recognition ( publication in Nature Communications ) International : three key agreements signed ; Chinese joint venture ready for first sales by the end of 2026 ; first product registrations in the Middle East in the first half of 2027 Half - year revenue of € 0.8M ( + 130 % ) , in line with the announced range , and a limited increase in operating expenses ( + 8 % , to € 5.5M ) Cash position of € 11.7M as of June 30 , 2026 , strengthened by the June capital increase , providing a cash runway to the end of 2027 Withdrawal of the financial ambitions communicated to the market for the 2026-2030 period ; Confidence in the acceleration of the growth trajectory as early as the second half of 2026 A strengthened strategic direction : to become a reference player in cardiometabolic products on an international scale Next event : Webinar with individual shareholders on Monday , October 12 at 6:00 PM ( CEST ) To register or log in Connection link La Rochelle , October 12 , 2026 ( 5:40 PM CEST ) - Valbiotis ( FR0013254851 - ALVAL , PEA / PME eligible ) , a French laboratory specializing in cardiometabolic health , announces its results for the first half of 2026 and provides an update on its roadmap and outlook . 1